An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe.
Denis Horgan, Marleen Jansen, Lada Leyens, Jonathan A Lal, Ralf Sudbrak, Erica Hackenitz, Ulrike Bußhoff, Wolfgang Ballensiefen, Angela Brand. Public Health Genomics 2014
Times Cited: 40
Times Cited: 40
Times Cited
Times Co-cited
Similarity
Working towards personalization in medicine: main obstacles to reaching this vision from today's perspective.
Lada Leyens, Denis Horgan, Jonathan A Lal, Kirsten Steinhausen, Kapaettu Satyamoorthy, Angela Brand. Per Med 2014
Lada Leyens, Denis Horgan, Jonathan A Lal, Kirsten Steinhausen, Kapaettu Satyamoorthy, Angela Brand. Per Med 2014
71
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu. Rev. Pharmacol. Toxicol. 2015
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu. Rev. Pharmacol. Toxicol. 2015
12
Implementation and utilization of genetic testing in personalized medicine.
Noura S Abul-Husn, Aniwaa Owusu Obeng, Saskia C Sanderson, Omri Gottesman, Stuart A Scott. 2014
Noura S Abul-Husn, Aniwaa Owusu Obeng, Saskia C Sanderson, Omri Gottesman, Stuart A Scott. 2014
10
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
A R Shuldiner, M V Relling, J F Peterson, J K Hicks, R R Freimuth, W Sadee, N L Pereira, D M Roden, J A Johnson, T E Klein,[...]. Clin. Pharmacol. Ther. 2013
A R Shuldiner, M V Relling, J F Peterson, J K Hicks, R R Freimuth, W Sadee, N L Pereira, D M Roden, J A Johnson, T E Klein,[...]. Clin. Pharmacol. Ther. 2013
10
Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey.
E J Stanek, C L Sanders, K A Johansen Taber, M Khalid, A Patel, R R Verbrugge, B C Agatep, R E Aubert, R S Epstein, F W Frueh. Clin. Pharmacol. Ther. 2012
E J Stanek, C L Sanders, K A Johansen Taber, M Khalid, A Patel, R R Verbrugge, B C Agatep, R E Aubert, R S Epstein, F W Frueh. Clin. Pharmacol. Ther. 2012
10
10
10
Virtual Clinical Trials, an Essential Step in Increasing the Effectiveness of the Drug Development Process.
Hans Lehrach. Public Health Genomics 2015
Hans Lehrach. Public Health Genomics 2015
44
Evidence based medicine: what it is and what it isn't.
D L Sackett, W M Rosenberg, J A Gray, R B Haynes, W S Richardson. BMJ 1996
D L Sackett, W M Rosenberg, J A Gray, R B Haynes, W S Richardson. BMJ 1996
10
Is precision medicine the route to a healthy world?
Denis Horgan, Angelo Paradiso, Gordon McVie, Ian Banks, Tom Van der Wal, Angela Brand, Mark Lawler. Lancet 2015
Denis Horgan, Angelo Paradiso, Gordon McVie, Ian Banks, Tom Van der Wal, Angela Brand, Mark Lawler. Lancet 2015
33
Implementing genomic medicine in the clinic: the future is here.
Teri A Manolio, Rex L Chisholm, Brad Ozenberger, Dan M Roden, Marc S Williams, Richard Wilson, David Bick, Erwin P Bottinger, Murray H Brilliant, Charis Eng,[...]. Genet. Med. 2013
Teri A Manolio, Rex L Chisholm, Brad Ozenberger, Dan M Roden, Marc S Williams, Richard Wilson, David Bick, Erwin P Bottinger, Murray H Brilliant, Charis Eng,[...]. Genet. Med. 2013
10
Personalised medicine: the cognitive side of patients.
Ilaria Cutica, Gordon Mc Vie, Gabriella Pravettoni. Eur. J. Intern. Med. 2014
Ilaria Cutica, Gordon Mc Vie, Gabriella Pravettoni. Eur. J. Intern. Med. 2014
13
Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin. Pharmacol. Ther. 2011
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin. Pharmacol. Ther. 2011
7
Pharmacogenetics in Europe: barriers and opportunities.
D Gurwitz, E Zika, M M Hopkins, S Gaisser, D Ibarreta. Public Health Genomics 2009
D Gurwitz, E Zika, M M Hopkins, S Gaisser, D Ibarreta. Public Health Genomics 2009
8
Ask not what personalized medicine can do for you--ask what you can do for personalized medicine.
Isabelle Budin-Ljøsne, Jennifer R Harris. Public Health Genomics 2015
Isabelle Budin-Ljøsne, Jennifer R Harris. Public Health Genomics 2015
27
Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU).
Kristine Sørensen, Jürgen M Pelikan, Florian Röthlin, Kristin Ganahl, Zofia Slonska, Gerardine Doyle, James Fullam, Barbara Kondilis, Demosthenes Agrafiotis, Ellen Uiters,[...]. Eur J Public Health 2015
Kristine Sørensen, Jürgen M Pelikan, Florian Röthlin, Kristin Ganahl, Zofia Slonska, Gerardine Doyle, James Fullam, Barbara Kondilis, Demosthenes Agrafiotis, Ellen Uiters,[...]. Eur J Public Health 2015
7
A tiered-layered-staged model for informed consent in personal genome testing.
Eline M Bunnik, A Cecile J W Janssens, Maartje H N Schermer. Eur. J. Hum. Genet. 2013
Eline M Bunnik, A Cecile J W Janssens, Maartje H N Schermer. Eur. J. Hum. Genet. 2013
7
Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Lada Leyens, Angela Brand. Public Health Genomics 2016
Lada Leyens, Angela Brand. Public Health Genomics 2016
25
What is personalized medicine: sharpening a vague term based on a systematic literature review.
Sebastian Schleidgen, Corinna Klingler, Teresa Bertram, Wolf H Rogowski, Georg Marckmann. BMC Med Ethics 2013
Sebastian Schleidgen, Corinna Klingler, Teresa Bertram, Wolf H Rogowski, Georg Marckmann. BMC Med Ethics 2013
7
Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab.
C Leopold, S Vogler, C Habl, A K Mantel-Teeuwisse, J Espin. Health Policy 2013
C Leopold, S Vogler, C Habl, A K Mantel-Teeuwisse, J Espin. Health Policy 2013
21
Pharmacogenomic information in drug labels: European Medicines Agency perspective.
F Ehmann, L Caneva, K Prasad, M Paulmichl, M Maliepaard, A Llerena, M Ingelman-Sundberg, M Papaluca-Amati. Pharmacogenomics J. 2015
F Ehmann, L Caneva, K Prasad, M Paulmichl, M Maliepaard, A Llerena, M Ingelman-Sundberg, M Papaluca-Amati. Pharmacogenomics J. 2015
7
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.
Shuji Ogino, Charles S Fuchs, Edward Giovannucci. Expert Rev. Mol. Diagn. 2012
Shuji Ogino, Charles S Fuchs, Edward Giovannucci. Expert Rev. Mol. Diagn. 2012
7
A revolution in healthcare: challenges and opportunities for personalized medicine.
Hans Lehrach. Per Med 2012
Hans Lehrach. Per Med 2012
75
European healthcare systems readiness to shift from 'one-size fits all' to personalized medicine.
Sebastian Schee Genannt Halfmann, Nikolaos Evangelatos, Peter Schröder-Bäck, Angela Brand. Per Med 2017
Sebastian Schee Genannt Halfmann, Nikolaos Evangelatos, Peter Schröder-Bäck, Angela Brand. Per Med 2017
60
Barriers for integrating personalized medicine into clinical practice: a qualitative analysis.
Mehdi Najafzadeh, Jennifer C Davis, Pamela Joshi, Carlo Marra. Am. J. Med. Genet. A 2013
Mehdi Najafzadeh, Jennifer C Davis, Pamela Joshi, Carlo Marra. Am. J. Med. Genet. A 2013
20
The theory of reference values: an unfinished symphony.
Gerard Siest, Joseph Henny, Ralph Gräsbeck, Peter Wilding, Claude Petitclerc, Josep M Queraltó, Peter Hyltoft Petersen. Clin. Chem. Lab. Med. 2013
Gerard Siest, Joseph Henny, Ralph Gräsbeck, Peter Wilding, Claude Petitclerc, Josep M Queraltó, Peter Hyltoft Petersen. Clin. Chem. Lab. Med. 2013
5
Whole genome sequencing as a diagnostic test: challenges and opportunities.
Caitlin C Chrystoja, Eleftherios P Diamandis. Clin. Chem. 2014
Caitlin C Chrystoja, Eleftherios P Diamandis. Clin. Chem. 2014
5
Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists.
Taku Obara, Shinya Abe, Michihiro Satoh, Sergio Ramón Gutiérrez Ubeda, Shoko Yoshimachi, Teruaki Goto. 2015
Taku Obara, Shinya Abe, Michihiro Satoh, Sergio Ramón Gutiérrez Ubeda, Shoko Yoshimachi, Teruaki Goto. 2015
33
Personalized diagnostics and biosensors: a review of the biology and technology needed for personalized medicine.
Minhaz Uddin Ahmed, Ishtiaq Saaem, Pae C Wu, April S Brown. Crit. Rev. Biotechnol. 2014
Minhaz Uddin Ahmed, Ishtiaq Saaem, Pae C Wu, April S Brown. Crit. Rev. Biotechnol. 2014
5
miRNAs as biomarkers of myocardial infarction: a step forward towards personalized medicine?
Emeline Goretti, Daniel R Wagner, Yvan Devaux. Trends Mol Med 2014
Emeline Goretti, Daniel R Wagner, Yvan Devaux. Trends Mol Med 2014
5
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).
F Ciardiello, D Arnold, P G Casali, A Cervantes, J-Y Douillard, A Eggermont, A Eniu, K McGregor, S Peters, M Piccart,[...]. Ann. Oncol. 2014
F Ciardiello, D Arnold, P G Casali, A Cervantes, J-Y Douillard, A Eggermont, A Eniu, K McGregor, S Peters, M Piccart,[...]. Ann. Oncol. 2014
5
Challenges and opportunities for medical directors in pathology and laboratory medicine: standardization, integration, and innovation.
James S Hernandez, Jane C Dale, Kevin E Bennet, Prathibha Varkey. Am. J. Clin. Pathol. 2010
James S Hernandez, Jane C Dale, Kevin E Bennet, Prathibha Varkey. Am. J. Clin. Pathol. 2010
28
Clinical necessity of partitioning of human plasma haptoglobin reference intervals by recently-discovered rs2000999.
Payman Shahabi, Gérard Siest, Bernard Herbeth, Ndeye Coumba Ndiaye, Sophie Visvikis-Siest. Clin. Chim. Acta 2012
Payman Shahabi, Gérard Siest, Bernard Herbeth, Ndeye Coumba Ndiaye, Sophie Visvikis-Siest. Clin. Chim. Acta 2012
22
Laboratory medicine: challenges and opportunities.
Xavier Bossuyt, Kurt Verweire, Norbert Blanckaert. Clin. Chem. 2007
Xavier Bossuyt, Kurt Verweire, Norbert Blanckaert. Clin. Chem. 2007
5
Challenges and opportunities for medical directors in pathology and laboratory medicine: standardization, integration, and innovation.
Subhash C Arya, James S Hernandez, Jane C Dale, Kevin E Bennet, Prathibha Varkey. Am. J. Clin. Pathol. 2010
Subhash C Arya, James S Hernandez, Jane C Dale, Kevin E Bennet, Prathibha Varkey. Am. J. Clin. Pathol. 2010
66
The highs and lows of tumor biomarkers: lost illusions.
Bohuslav Melichar. Clin. Chem. Lab. Med. 2015
Bohuslav Melichar. Clin. Chem. Lab. Med. 2015
66
Personalized (laboratory) medicine: a bridge to the future.
Mario Plebani, Giuseppe Lippi. Clin. Chem. Lab. Med. 2013
Mario Plebani, Giuseppe Lippi. Clin. Chem. Lab. Med. 2013
14
Mass spectrometry-based proteomics in Chest Medicine, Gerontology, and Nephrology: subgroups omics for personalized medicine.
Shih-Yi Lin, Wu-Huei Hsu, Cheng-Chieh Lin, Chao-Jung Chen. 2014
Shih-Yi Lin, Wu-Huei Hsu, Cheng-Chieh Lin, Chao-Jung Chen. 2014
18
Inter-individual variation of inflammatory markers of cardiovascular risks and diseases.
Hind Berrahmoune, John Lamont, Peter Fitzgerald, Sophie Visvikis-Siest. Clin. Chem. Lab. Med. 2005
Hind Berrahmoune, John Lamont, Peter Fitzgerald, Sophie Visvikis-Siest. Clin. Chem. Lab. Med. 2005
15
Biomedical research: increasing value, reducing waste.
Malcolm R Macleod, Susan Michie, Ian Roberts, Ulrich Dirnagl, Iain Chalmers, John P A Ioannidis, Rustam Al-Shahi Salman, An-Wen Chan, Paul Glasziou. Lancet 2014
Malcolm R Macleod, Susan Michie, Ian Roberts, Ulrich Dirnagl, Iain Chalmers, John P A Ioannidis, Rustam Al-Shahi Salman, An-Wen Chan, Paul Glasziou. Lancet 2014
5
Policies to aid the adoption of personalized medicine.
Charity Nofziger, Marisa Papaluca, Andre Terzic, Scott Waldman, Markus Paulmichl. Nat Rev Drug Discov 2014
Charity Nofziger, Marisa Papaluca, Andre Terzic, Scott Waldman, Markus Paulmichl. Nat Rev Drug Discov 2014
40
Personalized medicine and the clinical laboratory.
João Renato Rebello Pinho, Roberta Sitnik, Cristóvão Luis Pitangueira Mangueira. Einstein (Sao Paulo) 2014
João Renato Rebello Pinho, Roberta Sitnik, Cristóvão Luis Pitangueira Mangueira. Einstein (Sao Paulo) 2014
50
Omics and drug response.
Urs A Meyer, Ulrich M Zanger, Matthias Schwab. Annu. Rev. Pharmacol. Toxicol. 2013
Urs A Meyer, Ulrich M Zanger, Matthias Schwab. Annu. Rev. Pharmacol. Toxicol. 2013
5
Pharmacogenomics and individualized medicine: translating science into practice.
K R Crews, J K Hicks, C-H Pui, M V Relling, W E Evans. Clin. Pharmacol. Ther. 2012
K R Crews, J K Hicks, C-H Pui, M V Relling, W E Evans. Clin. Pharmacol. Ther. 2012
5
Charting a course for genomic medicine from base pairs to bedside.
Eric D Green, Mark S Guyer. Nature 2011
Eric D Green, Mark S Guyer. Nature 2011
5
Clinical pharmacogenetics implementation: approaches, successes, and challenges.
Kristin W Weitzel, Amanda R Elsey, Taimour Y Langaee, Benjamin Burkley, David R Nessl, Aniwaa Owusu Obeng, Benjamin J Staley, Hui-Jia Dong, Robert W Allan, J Felix Liu,[...]. Am J Med Genet C Semin Med Genet 2014
Kristin W Weitzel, Amanda R Elsey, Taimour Y Langaee, Benjamin Burkley, David R Nessl, Aniwaa Owusu Obeng, Benjamin J Staley, Hui-Jia Dong, Robert W Allan, J Felix Liu,[...]. Am J Med Genet C Semin Med Genet 2014
5
Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin. Pharmacol. Ther. 2012
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin. Pharmacol. Ther. 2012
5
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.